The only accurate crypto trading system I know …

Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.

Here's what our expert says you should buy before April 14.

John Bolla Biography and Net Worth

COO of Lantheus

Presently, John J. Bolla holds the position of Chief Supply Chain Officer & VP-Operations at Adare Pharmaceuticals, Inc. and Chief Operations Officer at Lantheus Medical Imaging, Inc.

In his past career he was Chief Operating Officer of Lantheus Holdings, Inc.

He received an undergraduate degree from the University of Central Florida.

What is John J. Bolla's net worth?: The estimated net worth of John J. Bolla is at least $3.94 million as of June 16th, 2020. Mr. Bolla owns 60,419 shares of Lantheus stock worth more than $3,939,923 as of April 25th. This net worth estimate does not reflect any other assets that Mr. Bolla may own. Learn More about John J. Bolla's net worth.
How do I contact John J. Bolla?: The corporate mailing address for Mr. Bolla and other Lantheus executives is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. Lantheus can also be reached via phone at (978) 671-8001 and via email at [email protected]. Learn More on John J. Bolla's contact information.
Has John J. Bolla been buying or selling shares of Lantheus?: John J. Bolla has not been actively trading shares of Lantheus over the course of the past ninety days. Most recently, John J. Bolla sold 2,422 shares of the business's stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $14.29, for a transaction totalling $34,610.38. Following the completion of the sale, the insider now directly owns 60,419 shares of the company's stock, valued at $863,387.51. Learn More on John J. Bolla's trading history.
Who are Lantheus' active insiders?: Lantheus' insider roster includes Minnie Baylor-Henry (Director), Gerard Ber (Director), Paul Blanchfield (Insider), John Bolla (COO), Michael Duffy (SVP), Mary Heino (CEO), Sam Leno (Director), Heinz Maeusli (Director), Brian Markison (Director), Robert Marshall, Jr. (CFO), Etienne Montagut (Insider), Daniel Niedzwiecki (Insider), Andrea Sabens (CAO), and Carol Walker (SVP). Learn More on Lantheus' active insiders.
Are insiders buying or selling shares of Lantheus?: During the last year, Lantheus insiders bought shares 1 times. They purchased a total of 60,431,039 shares worth more than $57,409,487.05. During the last year, insiders at the medical equipment provider sold shares 19 times. They sold a total of 148,672 shares worth more than $10,389,459.87. The most recent insider tranaction occured on April, 15th when CAO Andrea Sabens sold 341 shares worth more than $20,882.84. Insiders at Lantheus own 1.5% of the company. Learn More about insider trades at Lantheus.
Information on this page was last updated on 4/15/2024.

John J. Bolla Insider Trading History at Lantheus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/16/2020	Sell	2,422	$14.29	$34,610.38	60,419
2/27/2020	Sell	1,251	$15.79	$19,753.29	35,154
6/19/2019	Sell	1,747	$27.56	$48,147.32	37,155

John J. Bolla Buying and Selling Activity at Lantheus

Lantheus Company Overview

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Today's Range

Now: $64.10

$63.76

$64.80

50 Day Range

MA: $61.13

$56.37

$68.26

2 Week Range

Now: $64.10

$50.20

$100.85

Volume

32,908 shs

Average Volume

1,029,215 shs

Market Capitalization

$4.39 billion

P/E Ratio

13.81

Dividend Yield

N/A

Beta

0.53